摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-Prenylquercetin | 143724-75-8

中文名称
——
中文别名
——
英文名称
8-Prenylquercetin
英文别名
8-(3,3-dimethylallyl)quercetin;8-C-prenylquercetin;8-prenyl quercetin;2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-8-(3-methylbut-2-enyl)chromen-4-one
8-Prenylquercetin化学式
CAS
143724-75-8
化学式
C20H18O7
mdl
——
分子量
370.359
InChiKey
ZHTTWVRMGWQEOH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    652.9±55.0 °C(Predicted)
  • 密度:
    1.519±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    27
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    127
  • 氢给体数:
    5
  • 氢受体数:
    7

SDS

SDS:b68bfa5c9959f5a642223464a338d96f
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    8-Prenylquercetin硫酸二甲酯potassium carbonate 作用下, 以 丙酮 为溶剂, 反应 6.0h, 以84%的产率得到3,3',4',7-tetramethoxy-8-C-prenylquercetin
    参考文献:
    名称:
    的区域选择性合成Ç -prenylated黄酮经由分子内[1,3]或[1,5]变换反应通过酸性粘土催化
    摘要:
    异戊二烯侧链和二氢吡喃基骨架存在于许多天然和合成的生物活性类黄酮中。用于合成一个高效和区域选择性方法Ç -prenylated黄酮经由分子内[1,3]或[1,5]移位5-反应ö -prenylflavonoids通过硅酸镁载体或蒙脱土催化进行说明。Florisil催化5- O-异戊烯基类黄酮的分子内[1,5]转化反应,从而获得8 - C-异戊烯基化黄酮,蒙脱土K10表现出优异的选择性,可促进分子内[1,3]转化反应获得6- C。-异戊二烯黄酮与Florisil和Montmorillonite KSF的比较。该方法提供了在温和条件下使用市售和廉价的催化剂以高收率选择性选择性地生物合成重要的生物学上重要的C-戊烯基黄酮类化合物的实用方法。
    DOI:
    10.1016/j.tetlet.2019.151138
  • 作为产物:
    描述:
    槲皮素吡啶 、 tris(6,6,7,7,8,8-heptafluoro-2,2-dimethyl-3,5-octadionato)europium(III) 、 偶氮二甲酸二异丙酯乙二胺三苯基膦 作用下, 以 四氢呋喃甲苯 为溶剂, 反应 18.5h, 生成 8-Prenylquercetin
    参考文献:
    名称:
    槲皮素和青蒿素异戊二烯化对生物利用度和生物活性的影响
    摘要:
    类黄酮是一大类多酚化合物,广泛存在于高等植物、大多数天然食品和饮料中。它们可以被认为是膳食酚类物质,对人和动物的生理具有许多促进健康的作用,具有广泛的生物医学和营养功能,例如激活或抑制脂肪氧化酶和环氧合酶等酶,致癌物质的解毒和化学预防。从化学的角度来看,这些芳香族化合物可根据芳香族 B 环在 C 环上的位置、不饱和度和氧化程度、羟基的位置及其官能化程度分为六个亚组。在类黄酮之间,异戊二烯化的那些代表了自然界中发生的一个独特的类别,其中C-异戊二烯化是最常见的,而O-异戊二烯化很少存在。这种亲脂性官能团在类黄酮支架的不同位置的存在有时会由于生物利用度的增加而导致其生物活性的相关变化。利用异戊二烯化黄酮类化合物在自然界中的有限发生率,我们评估了C - 和O的合成-异戊二烯化衍生物,源自两种黄酮类化合物槲皮素和青蒿素,旨在探索构效关系。结果表明异戊二烯化显着增加了黄酮类化合物在癌细胞 HeLa
    DOI:
    10.1016/j.chemphyslip.2021.105137
点击查看最新优质反应信息

文献信息

  • Hypoglycemic and hypolipidemic dual activities of extracts and flavonoids from Desmodium caudatum and an efficient synthesis of the most potent 8-prenylquercetin
    作者:Yinan Zhang、Xiaoting Zhang、Zhiyi Xiao、Xinying Zhang、Hua Sun
    DOI:10.1016/j.fitote.2021.105083
    日期:2022.1
    functional food acting on multi-targets. The hypoglycemic and hypolipidemic dual activities of the root, stems and leaves of Desmodium caudatum, which is used for traditional Chinese medicine, was evaluated. Twelve extracts with different extraction conditions were prepared and extract 9 was find to exhibit potential inhibitory activities of fructose-1, 6-bisphosphatase (FBPase), α-glucosidase, and
    由于糖脂代谢紊乱往往是单靶点治疗无法控制血糖和血脂平等并发症,因此寻找新的潜在药物或功能性食品作用于多靶点已迫在眉睫。大钱草根茎叶的降糖降血脂双重作用, 用于中药, 进行了评价。制备了 12 种不同提取条件的提取物,发现提取物 9 对果糖 1、6-双磷酸酶 (FBPase)、α-葡萄糖苷酶和胰脂肪酶具有潜在的抑制活性,并促进细胞葡萄糖消耗并降低细胞内脂质含量. 从提取物 9 中分离鉴定出 5 种黄酮类化合物,其中 8-异戊二烯槲皮素表现出强效的 α-葡萄糖苷酶 (IC 50  = 4.38 μM) 和 FBPase (IC 50  = 3.62 μM) 双重抑制活性,比阿卡波糖 (IC) 高 75 倍。50  = 330.10 μM),与 AMP (IC 50 = 2.92 微米)。此外,8-异戊二烯槲皮素能够促进葡萄糖消耗并降低脂质含量。此外,以廉价、市售的芦丁为原料,通过6个步骤高
  • Microbial Transformation of Prenylquercetins by Mucor hiemalis
    作者:Fubo Han、Yina Xiao、Ik-Soo Lee
    DOI:10.3390/molecules25030528
    日期:——
    revealed in many studies that the biological activities of flavonoids could be improved after glucosylation. Three prenylated quercetins were prepared in this study, and microbial transformation was carried out in order to identify derivatives of prenylquercetins with increased water solubility and improved bioavailability. The fungus M. hiemalis was proved to be capable of converting prenylquercetins into
    槲皮素是分布最广泛的类黄酮之一,已被发现具有多种生物活性,包括抗氧化、抗癌和抗炎作用。据报道,类黄酮生物活性增强通常与核异戊二烯化密切相关,如 8-异戊二烯槲皮素和 5'-异戊二烯槲皮素所示。许多研究还表明,糖基化后可以提高黄酮类化合物生物活性。本研究制备了三种异戊二烯槲皮素,并进行了微生物转化,以鉴定具有增加溶性和改善生物利用度的异戊二烯槲皮素生物。真菌 M. hiemalis 被证明能够将异戊二烯槲皮素转化为更具极性的代谢物,并被选择用于制备发酵。获得了六种新的糖基化代谢物,并通过核磁共振和质谱分析阐明了它们的化学结构。所有微生物代谢物都显示出溶性的改善。
  • HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR
    申请人:Meiji Seika Kaisha, Ltd.
    公开号:EP1602354A1
    公开(公告)日:2005-12-07
    The present invention intends to provide a composition for hair treatment containing γ-polyglutamic acid or a salt thereof, a hair cosmetic for damaged hair containing such a composition, and their uses. The composition for hair treatment containing γ-polyglutamic acid or a salt thereof and the hair cosmetic for damaged hair of the present invention have excellent improvement effects on the strength and frictional force of hair, so that they can provide tension, elasticity, or the like to damage hair to prevent or alleviate split hair and broken hair as well as improvements in combing and touch. Furthermore, they also exert effects of moisture retention inherent to γ-polyglutamic acid or a salt thereof, preventing or improving effects on the generation of dandruff on the basis of such effects, preventing effects on the feeling of stickiness or creak, and various effectiveness including appropriate residual tendency to hair in a simultaneous manner, respectively.
    本发明旨在提供一种含有γ-聚谷酸或其盐的头发治疗组合物、一种含有这种组合物的用于受损头发的护发化妆品及其用途。本发明的含有γ-聚谷酸或其盐的头发治疗组合物和用于受损头发的护发化妆品对头发的强度和摩擦力有很好的改善效果,因此它们可以为受损头发提供张力、弹性等,以防止或减轻头发分叉和断裂,并改善梳理和触感。此外,它们还能分别发挥γ-聚谷酸或其盐固有的保湿效果、在此基础上防止或改善头皮屑产生的效果、防止粘腻感或吱吱作响的效果,以及包括同时对头发产生适当残留倾向在内的各种功效。
  • COSMETIC COMPOSITION
    申请人:Chisso Corporation
    公开号:EP2116224A1
    公开(公告)日:2009-11-11
    The problem of the present invention is to provide a cosmetic composition, which has a moisturizing effect, and whose ability to inhibit hyaluronidase activity is high. According to the present invention, by using one or more substances selected from sulfated cellulose and a salt thereof in combination with polyhydric alcohol, the moisturizing effect of sulfated cellulose and the ability to inhibit hyaluronidase activity can be further improved, and thereby the above-described problem can be solved. In addition, the present invention can provide a cosmetic composition having excellent stability through inclusion of an electrolyte having pH buffering ability.
    本发明的问题是提供一种具有保湿效果且抑制透明质酸酶活性能力强的化妆品组合物。根据本发明,通过将一种或多种选自硫酸纤维素及其盐的物质与多元醇结合使用,可以进一步提高硫酸纤维素的保湿效果和抑制透明质酸酶活性的能力,从而解决上述问题。此外,本发明还通过加入具有 pH 缓冲能力的电解质,提供了一种稳定性极佳的化妆品组合物。
  • Foam cell specific Liver X Receptor (LXR) alpha agonist, SIRT1 inhibitors as well as p300 inhibitors as pharmaceutically active agents
    申请人:Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    公开号:EP2759295A1
    公开(公告)日:2014-07-30
    The present invention relates to compound (I) and its stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable other LXRα agonist, carrier, excipient and/or diluents. Said compound (I), an LXRα agonist has been identified as useful for the prophylaxis and treatment of atherosclerosis and cardiovascular diseases. Further, the present invention refers to compound (II) and its stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said compound (II), a SIRT1 inhibitor has been identified as useful for the prophylaxis and treatment of neurodegenerative diseases or cancer. Furthermore, the present invention discloses compound (III) and its stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said compound (III), a p300 inhibitor has been identified as useful for the prophylaxis and treatment of cancer, metabolic, inflammatory, neurodegenerative or cardiovascular diseases.
    本发明涉及化合物(I)及其立体异构体、原药、溶液剂、合物和/或这些化合物的药学上可接受的盐,以及含有至少一种这些化合物和药学上可接受的其他 LXRα 激动剂、载体、赋形剂和/或稀释剂的药物组合物。所述化合物(I)是一种 LXRα 激动剂,已被确认可用于预防和治疗动脉粥样硬化和心血管疾病。 此外,本发明还涉及化合物(II)及其立体异构体、原药、溶液剂、合物和/或这些化合物的药学上可接受的盐,以及含有至少一种这些化合物和药学上可接受的载体、赋形剂和/或稀释剂的药物组合物。所述化合物(II)是一种 SIRT1 抑制剂,已被确认可用于预防和治疗神经退行性疾病或癌症。 此外,本发明还公开了化合物(III)及其立体异构体、原药、溶液剂、合物和/或这些化合物的药学上可接受的盐,以及含有至少一种这些化合物和药学上可接受的载体、赋形剂和/或稀释剂的药物组合物。所述化合物(III)是一种 p300 抑制剂,已被确认可用于预防和治疗癌症、代谢性疾病、炎症、神经退行性疾病或心血管疾病。
查看更多